Radiodermatitis

disease
On this page

Also known as Dermatitides, radiation recallDermatitides, radiation-induceddermatitis radiationdermatitis, radiation induceddermatitis, radiation recalldermatitis, radiation-inducedradiation dermatitisradiation induced dermatitisradiation recall Dermatitidesradiation recall dermatitisradiation recall reactionradiation recall reactionsradiation-induced Dermatitidesradiation-induced dermatitisRadiodermatitidesreaction, radiation recallreactions, radiation recallrecall reaction, radiationrecall reactions, radiation

Summary

Radiodermatitis (MONDO:0043771) is a disease and 107 clinical trials. Top therapeutic interventions include calcipotriene, cianidanol, and dimethyl sulfoxide. A subtype of dermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 107

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameradiodermatitis
Mondo IDMONDO:0043771
MeSHD011855
ICD-10-CML58
NCITC3349
SNOMED CT49084001
GARD0025867
Is cancer (heuristic)no

Also known as: Dermatitides, radiation recall · Dermatitides, radiation-induced · dermatitis radiation · dermatitis, radiation induced · dermatitis, radiation recall · dermatitis, radiation-induced · radiation dermatitis · radiation induced dermatitis · radiation recall Dermatitides · radiation recall dermatitis · radiation recall reaction · radiation recall reactions · radiation-induced Dermatitides · radiation-induced dermatitis · Radiodermatitides · radiodermatitis · reaction, radiation recall · reactions, radiation recall · recall reaction, radiation · recall reactions, radiation

Disease family

This is a subtype of dermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorderdermatitisradiodermatitis

Related subtypes (32): spongiotic dermatitis, atopic eczema, psoriasis, contact dermatitis, urticaria, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, lichen planus, neurodermatitis, neurotic excoriation, parapsoriasis, pityriasis rosea, seborrheic dermatitis, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, hydroa vacciniforme, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, food dermatitis

Subtypes (1): photosensitivity disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
AloePhase 3 (in late-stage trials)
UreaPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Calcipotriene, Chamomile, Curcumin, Mometasone Furoate, Mupirocin, Polyethylene Glycol.

Clinical trials & evidence

Clinical trials

Clinical trials: 107.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified65
PHASE213
PHASE311
PHASE1/PHASE26
PHASE16
PHASE2/PHASE34
PHASE41
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02495064PHASE4UNKNOWNMometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas’ Patients
NCT06915857PHASE3RECRUITINGTopical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Prone Position
NCT07066280PHASE3RECRUITINGModulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
NCT07149506PHASE3ENROLLING_BY_INVITATIONOral or Topical Catechins for Radiation Dermatitis
NCT07353671PHASE2/PHASE3RECRUITINGTopical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
NCT00481884PHASE3COMPLETEDComparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients
NCT00876642PHASE3COMPLETEDTrial Comparing Best Supportive Care to Aloe Vera Gel
NCT01246973PHASE2/PHASE3COMPLETEDOral Curcumin for Radiation Dermatitis
NCT02247830PHASE3COMPLETEDManagement Radiodermatitis in Patients With Breast or Head and Neck Cancer
NCT02251392PHASE3UNKNOWNEvaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis
NCT02369835PHASE3COMPLETEDModified Dakin’s Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
NCT02839473PHASE3COMPLETEDHydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial
NCT03883828PHASE2/PHASE3COMPLETEDBacterial Decolonization to Prevent Radiation Dermatitis
NCT04059809PHASE2/PHASE3COMPLETEDPhotobiomodulation for Breast Cancer Radiodermatitis
NCT04239560PHASE3COMPLETEDPreventive Effect of Boron-based Gel on Radiation Dermatitis
NCT04300829PHASE3UNKNOWNCicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients
NCT07029178PHASE2RECRUITINGTaurine’s Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis
NCT00445250PHASE2UNKNOWNThe Role of Calcipotriol as Radioprotector of Skin
NCT01513278PHASE1/PHASE2COMPLETEDStudy of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer
NCT01544504PHASE1/PHASE2WITHDRAWNExploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy
NCT02051907PHASE2UNKNOWNClinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis
NCT02249884PHASE2COMPLETEDDose-Response Curve: Interventions to Prevent and Treat Radiodermatitis
NCT02289365PHASE2UNKNOWNOrally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients
NCT02534129PHASE1/PHASE2TERMINATEDTopical Use of Difinsa53™ to Prevent Radiation Dermatitis
NCT02556632PHASE2COMPLETEDProphylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
NCT02729324PHASE2UNKNOWNComparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT
NCT03494205PHASE2COMPLETEDUrtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis
NCT03716583PHASE2COMPLETEDMelatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer
NCT04149522PHASE2TERMINATEDEvaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer
NCT04261387PHASE1/PHASE2COMPLETEDLUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients
NCT04617730PHASE1/PHASE2UNKNOWNEfficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.
NCT04888234PHASE2UNKNOWNEvaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis.
NCT05269160PHASE1/PHASE2TERMINATEDTopical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
NCT05505214PHASE2WITHDRAWNTopical Steroids & Bacterial Decolonization for Radiation Dermatitis
NCT05693597PHASE2COMPLETEDEvaluation of the Effect of Nigella Sativa for the Prophylaxis to Radiation Induced Dermatitis in Breast Cancer Patients
NCT01263366PHASE1TERMINATEDExploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients
NCT01367990PHASE1TERMINATEDExploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy
NCT01714973PHASE1COMPLETEDStudy of ST266 Versus Saline in Treating Skin Irritation From Radiation
NCT04238728PHASE1COMPLETEDSilverlon to Reduce Radiation Dermatitis
NCT05114226PHASE1UNKNOWNA Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CALCIPOTRIENE41
CIANIDANOL41
DIMETHYL SULFOXIDE41
MOMETASONE FUROATE41
MUPIROCIN41
NOREPINEPHRINE41
PETROLATUM, WHITE41
SAPROPTERIN41
SODIUM HYPOCHLORITE41
SULFADIAZINE, SILVER41
UREA41
ALOE31
CURCUMIN31
TAURINE31
TROLAMINE22
(+)-EPICATECHIN21
(-)-EPICATECHIN21
CHEMBL43203
CHEMBL479365801
CHEMBL181438901
CHEMBL8094101
CHEMBL456377301
CHEMBL479696101
CHEMBL406330401
CATECHIN01